Pricing Log in Create free account

Eupraxia Pharmaceuticals Inc. (EPRX) vs Oculis Holding AG (OCS)

Eupraxia Pharmaceuticals Inc. and Oculis Holding AG are both Biotechnology companies. Eupraxia Pharmaceuticals Inc. and Oculis Holding AG are of similar size ($429.1M and $421.6M). Eupraxia Pharmaceuticals Inc. has the higher net margin (0.00% vs −8,709.4%) and the higher return on invested capital (0.00% vs −12,858.7%). Across the 13 metrics below, Eupraxia Pharmaceuticals Inc. leads on 8 and Oculis Holding AG on 5.

Valuation

Metric EPRX OCS Biotechnology median
P/E n/m n/m 10.60
P/S n/m 393.17 9.40
P/B 4.52 1.80 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 175.67 9.02
Earnings yield (14.46%) (23.24%) (32.88%)
Free cash flow yield (8.45%) (18.69%) (23.13%)

Profitability

Metric EPRX OCS Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% (9,551.41%) 0.00%
Net margin 0.00% (8,709.42%) 0.00%
Free cash flow margin 0.00% (7,237.57%) 0.00%
Return on equity (117.82%) (48.81%) (51.96%)
Return on assets (64.44%) (41.38%) (46.06%)
Return on invested capital 0.00% (12,858.67%) 0.00%

Growth

Metric EPRX OCS Biotechnology median
Revenue growth (TTM) — 25.01% 6.76%
EPS growth (last fiscal year) (35.53%) 5.39% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric EPRX OCS Biotechnology median
Debt to equity 0.01 0.01 0.00
Current ratio 16.00 10.41 4.97
Net debt to EBITDA 2.11 2.60 1.01

Dividend

Metric EPRX OCS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric EPRX OCS Biotechnology median
Market cap 429.13m 421.63m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack